• Shaikh Mohmed Adnan Mohmed Javid
• Vrunda Dimpalbhai Chhatrala
• Lency Sanjaybhai Kathiriya
• Jignesh Salunke
• Mishri F Patel

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and behavioral changes, with an increasing global prevalence, particularly among the elderly and females. The pathogenesis of AD is closely linked to the accumulation of amyloid-beta plaques in the brain, a key target in therapeutic development. Donanemab, a humanized monoclonal antibody designed to target the N-terminal pyroglutamate amyloid-beta (N3pE) epitope, has emerged as a promising disease-modifying therapy for early-stage Alzheimer's disease. Clinical trials, including the pivotal Phase 2 TRAILBLAZER-ALZ study, have demonstrated Donanemab's efficacy in reducing amyloid plaque burden and slowing cognitive decline, leading to its accelerated approval by the FDA. The ongoing Phase 3 trials aim to further establish its long-term efficacy and safety, with a particular focus on amyloid clearance and cognitive outcomes. Despite its potential, the introduction of Donanemab raises ethical considerations regarding access and affordability, highlighting the need for equitable distribution of this advanced therapy. As research continues, Donanemab represents a significant step forward in the treatment of Alzheimer's disease, offering new hope for patients and transforming the management of this challenging condition.

Alzheimer’s disease, Donanemab, TRAILBLAZER-ALZ

"TARGETING AMYLOID PLAQUES WITH DONANEMAB: A COMPREHENSIVE REVIEW OF CLINICAL EFFICACY AND FUTURE PROSPECTS IN ALZHEIMER’S DISEASE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 8, page no.e147-e151, August-2024, Available :http://www.jetir.org/papers/JETIR2408416.pdf

"TARGETING AMYLOID PLAQUES WITH DONANEMAB: A COMPREHENSIVE REVIEW OF CLINICAL EFFICACY AND FUTURE PROSPECTS IN ALZHEIMER’S DISEASE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 8, page no. ppe147-e151, August-2024, Available at : http://www.jetir.org/papers/JETIR2408416.pdf